MIRACLE Mechanically Interlocked Radiotracers Chelators for Efficient Cancer Therapy
- Coordinator
- University of Warwick, United Kingdom
- Runs
- 1 September 2026 to 31 August 2028
- Status
- Running
- EU funding
- €260k
- Total cost
- —
- Partners
- 2 organisations in 2 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101282487
What the project is doing
In the project's own words, from its summary on CORDIS.
Cancer is a leading global cause of death, with cases projected to rise sharply over the next decades. Radionuclide therapy (RNT) offers a highly selective alternative to conventional radiation treatments, using radiometal chelates for targeted tumour eradication. Despite clinical successes, current radiotracers face limitations including off-target toxicity, suboptimal pharmacokinetics, and insufficient stability. Mechanically Interlocked RAdiotracers CheLators (MIRACLEs) address these challenges by developing mechanically interlocked molecules (MIMs), such as rotaxanes and catenanes, as next-generation radiotracers.
These structures enable modular synthesis, tunable dynamics, and stimulus-responsiveness, allowing “smart” tracers with enhanced protein targeting, biodistribution control and metabolic stability. By integrating DOTA/DO3A scaffolds within mechanically interlocked architectures, mechanical bonds decouple thermodynamic affinity from kinetic inertness, providing steric shielding and addressing a key failure mode of conventional radiochelates.
This project will generate mechanically interlocked radiotracers (MIRTs) with improved in vivo stability, precise tissue-specific dosimetry, and efficient clearance. By combining supramolecular chemistry with radiopharmaceutical design, MIRACLE aims to deliver radiotheranostic agents with superior selectivity, safety and translational potential for clinical oncology.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| University of Warwick | Coventry | United Kingdom | Coordinator |
| Universitat Zurich | Zurich | Switzerland | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI